Natera

D

الأسعار متأخرة 15 دقيقة

ملف شركة Natera

الرئيس التنفيذي

Steven Leonard Chapman

عدد الموظفين

6,138

المقر الرئيسي

13011 McCallen Pass Building A, Austin, TX 78753, US

القطاع

الرعاية الصحية

الصناعة

التشخيص والأبحاث الطبية

تاريخ الطرح العام الأولي

1 يوليو 2015

البورصة

NASDAQ

رمز ISIN

US6323071042

الموقع الالكتروني:natera.com

عن الشركة

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

عدد الموظفين

كان لدى شركة Natera نحو 6,135 موظف في نهاية السنة المالية 2025 (31 ديسمبر 2025)، بحسب تقريرها السنوي. أي بزيادة 38.7% عن العام السابق.

عدد الموظفين في نهاية كل سنة مالية كما تذكره الشركة في تقريرها السنوي (⁦10-K⁩)؛ والإيرادات وصافي الدخل لكل موظف هي أرقام السنة المالية مقسومة على هذا العدد.

من يملك شركة Natera

امتلكت المؤسسات مثل الصناديق والبنوك وشركات التأمين 96.3% من أسهم شركة Natera في 30 يونيو 2026، وأفصحت 886 مؤسسة منها عن ملكيتها لهيئة الأوراق المالية الأمريكية؛ ويملك الباقي المستثمرون الأفراد ومساهمون آخرون.

أسئلة شائعة حول شركة Natera